Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stacy R. Lindborg
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Beta
- 1.98
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -42.61
Financials
Revenue
$0.00-100.0%Net Income
$-2.81MEBITDA
$-2.67MFree Cash Flow
$-4.06BEPS (diluted)
$-0.54Shares Outstanding (diluted)
5.23M+3837.8%Operating Expenses
$2.79MCash & Debt
$6.86MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-14.49M | $-6.83 |
| 2024 | $0.00 | $-18.62M | $-21.10 |
| 2023 | $0.00 | $-19.51M | $-28.14 |
| 2022 | $500.0K | $-35.90M | $-65.55 |
| 2021 | $500.0K | $-20.77M | $-748.77 |
| 2020 | $500.0K | $-21.48M | $-131.51 |
| 2019 | $500.0K | $-16.85M | $-151.01 |
| 2018 | $500.0K | $-11.88M | $-132.23 |
| 2017 | $500.0K | $-20.40M | $-532.22 |
| 2016 | $500.0K | $-22.05M | $-2328.26 |
| 2015 | $500.0K | $-22.46M | $-2821.30 |
| 2014 | $500.0K | $-25.49M | $-3780.00 |
| 2013 | $500.0K | $-8.25M | $-2602.17 |
| 2012 | $0.00 | $-26.57M | $-9367.82 |
Valuation
IMNNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-33.33%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·7d ago·Negative
…inal Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), (“IMUNON” or the “Company”), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of the Company's newly designated, non-c…
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001 Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J.
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001 Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript Imunon, Inc. (IMNN) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.61 per share
Typical surprise +30.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.54 vs $-0.87beat
- Tue, May 12$-0.84 vs $-1.22beat
- Tue, Mar 31$-1.29 vs $-1.43beat
- Thu, Nov 13$-1.16 vs $-1.20beat
- Tue, Aug 5$-1.87 vs $-3.09beat
- Mon, May 12$-3.65 vs $-4.56beat
Estimates and results for IMNN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMNN officers and directors.
- Bought
- $29k
- Sold
- $38k
1 trade
6 trades
- Eylward Susansold
- Eylward Susansold
- Eylward Susansold
- Eylward Susansold
- Eylward Susansold
- Eylward Susansold
- Braun Donald Pbought
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMNN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.